公开(公告)号：US09834590B2

公开(公告)日：2017-12-05

申请号：US14872947

申请日：2015-10-01

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Dario Campana ,  Chihaya Imai

IPC: C07K14/705 ,  C07K16/28 ,  C07K14/47 ,  C12N5/0783 ,  A61K39/395 ,  C07K14/725

CPC classification number: C07K14/70578 ,  A61K39/395 ,  C07K14/47 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2896 ,  C07K2319/32 ,  C12N5/0646 ,  C12N2501/23 ,  C12N2502/11 ,  C12N2502/99

Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.

公开(公告)号：US20170321224A1

公开(公告)日：2017-11-09

申请号：US15445635

申请日：2017-02-28

Applicant: St. Jude Children's Research Hospital

Inventor： Julia Lea Hurwitz ,  Toru Takimoto ,  Charles John Russell ,  Allen Portner ,  Karen Slobod

IPC: C12N15/86 ,  C07K16/08 ,  C12N7/00 ,  C07K14/005 ,  A61K39/00

CPC classification number: C12N15/86 ,  A61K2039/5254 ,  A61K2039/5256 ,  C07K14/005 ,  C07K16/08 ,  C12N7/00 ,  C12N2760/18534 ,  C12N2760/18634 ,  C12N2760/18734 ,  C12N2760/18821 ,  C12N2760/18822 ,  C12N2760/18834 ,  C12N2760/18843

Abstract: The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.

公开(公告)号：US20170304293A1

公开(公告)日：2017-10-26

申请号：US15520756

申请日：2015-10-16

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL

Inventor： Heather S. Smallwood ,  Marie Morfouace ,  Martine F. Roussel ,  Paul G. Thomas

IPC: A61K31/4745 ,  A61K31/7004 ,  A61K31/555 ,  A61K31/519 ,  A61K31/505 ,  A61K31/4439 ,  A61K31/277 ,  A61K31/427 ,  A61K31/4174 ,  A61K31/416 ,  A61K31/415 ,  A61K31/365 ,  A61K31/352 ,  A61K31/433 ,  A61K45/06

CPC classification number: A61K31/4745 ,  A61K31/277 ,  A61K31/34 ,  A61K31/352 ,  A61K31/365 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/505 ,  A61K31/519 ,  A61K31/555 ,  A61K31/7004 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention generally relates to methods of treating viral infections using known drugs and pharmaceutical compositions comprising same. More specifically, the disclosed methods are useful for the treatment of viral infections that are enveloped viruses. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20170283482A1

公开(公告)日：2017-10-05

申请号：US15470678

申请日：2017-03-27

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Dario Campana ,  Chihaya Imai

IPC: C07K14/705 ,  C07K14/47 ,  C07K16/28 ,  C07K14/725 ,  A61K39/395 ,  C12N5/0783

CPC classification number: C07K14/70578 ,  A61K39/395 ,  C07K14/47 ,  C07K14/7051 ,  C07K14/70517 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2896 ,  C07K2319/32 ,  C12N5/0646 ,  C12N2501/23 ,  C12N2502/11 ,  C12N2502/99

Abstract: The present invention relates to a chimeric receptor capable of signaling both a primary and a co-stimulatory pathway, thus allowing activation of the co-stimulatory pathway without binding to the natural ligand. The cytoplasmic domain of the receptor contains a portion of the 4-1BB signaling domain. Embodiments of the invention relate to polynucleotides that encode the receptor, vectors and host cells encoding a chimeric receptor, particularly including T cells and natural killer (NK) cells and methods of use.

公开(公告)号：US09682993B2

公开(公告)日：2017-06-20

申请号：US14650826

申请日：2013-12-09

Applicant: ST. JUDE CHILDREN'S RESEARCH HOSPITAL

Inventor： Thomas R Webb ,  Chandraiah Lagisetti

IPC: C07D493/10 ,  C07D309/10 ,  A61K31/351

CPC classification number: C07D493/10 ,  A61K31/351 ,  C07D309/10

Abstract: In one aspect, the invention relates to compounds having anticancer activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended to be used as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

公开(公告)号：US20170151324A1

公开(公告)日：2017-06-01

申请号：US15375664

申请日：2016-12-12

Applicant: Icahn School of Medicine at Mount Sinai ,  St. Jude Children's Research Hospital ,  The United States of America, As Represented by the Secretary of Agriculture

Inventor： Peter Palese ,  Adolfo Garcia-Sastre ,  Richard J. Webby ,  Juergen A. Richt ,  Robert G. Webster ,  Kelly M. Lager

IPC: A61K39/145 ,  C12N7/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/544 ,  A61K2039/552 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171

Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

公开(公告)号：US20170128749A1

公开(公告)日：2017-05-11

申请号：US15370022

申请日：2016-12-06

Applicant: Purdue Research Foundation ,  St. Jude Children's Research Hospital, Inc.

Inventor： Vadim Moskvin ,  Keith Michael Stantz

IPC: A61N5/10 ,  A61B8/08

CPC classification number: A61N5/1071 ,  A61B8/08 ,  A61B8/0833 ,  A61B8/483 ,  A61B2019/524 ,  A61N5/1031 ,  A61N5/1039 ,  A61N5/1075 ,  A61N2005/1034 ,  A61N2005/1076 ,  A61N2005/1087

Abstract: A method of verifying therapeutic proton beam delivery accuracy by ultrasound tomographic imaging to map three dimensional (3D) proton dose through the detection of ionizing radiation induced thermo-acoustic signal from the proton beam.

公开(公告)号：US20170049859A1

公开(公告)日：2017-02-23

申请号：US15254984

申请日：2016-09-01

Applicant: UCL BUSINESS PLC ,  ST. JUDE CHILDREN'S RESEARCH HOSPITAL

Inventor： Amit Nathwani ,  Jenny McIntosh ,  Edward Tuddenham ,  Andrew Davidoff

IPC: A61K38/37

CPC classification number: A61K38/37 ,  A01K67/0275 ,  A01K2227/105 ,  A01K2267/01 ,  A61K48/00 ,  C07K14/755

Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating haemophilia, e.g. haemophilia A, and a method for the preparation of a parvoviral gene delivery vector.

Abstract translation: 提供了包含编码功能性因子VIII蛋白的核苷酸序列的核酸分子，其中编码因子VIII蛋白的B结构域的核苷酸序列的部分长度在90和111个核苷酸之间，并编码氨基酸 序列包含与SEQ ID NO：4具有至少85％同一性的序列，其包含六个天冬酰胺残基。 还提供了功能性因子VIII蛋白，包含上述核酸分子的载体，宿主细胞，转基因动物，治疗血友病的方法，例如， 血友病A，以及用于制备细小病毒基因递送载体的方法。

公开(公告)号：US20170029777A1

公开(公告)日：2017-02-02

申请号：US15114259

申请日：2015-01-23

Applicant: St. Jude Children's Research Hospital, Inc.

Inventor： Asha PILLAI

IPC: C12N5/0783 ,  A61K39/00 ,  A61K35/17

CPC classification number: C12N5/0646 ,  A61K35/17 ,  A61K39/001 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/57 ,  A61K2039/577 ,  C12N2500/36 ,  C12N2501/05 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2506/11

Abstract: The present invention is directed to novel methods of producing ex vivo natural killer T (NKT) cells, and therapeutic uses thereof for treatment of certain conditions including cancer, autoimmunity, inflammatory disorders, allergic disorders, tissue transplant-related disorders, and infections.

Abstract translation: 本发明涉及用于制备离体天然杀伤T（NKT）细胞的新方法及其治疗某些病症（包括癌症，自身免疫，炎性疾病，过敏性疾病，组织移植相关病症和感染）的治疗用途。

公开(公告)号：US09549975B2

公开(公告)日：2017-01-24

申请号：US14636651

申请日：2015-03-03

Applicant: Icahn School of Medicine at Mount Sinai ,  St. Jude Children's Research Hospital ,  The United States of America, As Represented by the Secretary of Agriculture

Inventor： Peter Palese ,  Adolfo Garcia-Sastre ,  Richard J. Webby ,  Juergen A. Richt ,  Robert G. Webster ,  Kelly M. Lager

IPC: A61K39/145 ,  A61K39/12 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/544 ,  A61K2039/552 ,  A61K2039/58 ,  C12N7/00 ,  C12N2760/16034 ,  C12N2760/16061 ,  C12N2760/16121 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171

Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.

Abstract translation: 本发明通常涉及具有拮抗细胞干扰素（IFN）应答能力受损的减毒猪流感病毒，以及在疫苗和药物制剂中使用这种减毒病毒。 特别地，本发明涉及具有修饰猪NS1基因的减毒猪流感病毒，其减少或消除NS1基因产物拮抗细胞IFN应答的能力。 这些病毒在体内复制，但表现出降低的复制，毒力和增加的衰减，因此非常适合用于活病毒疫苗和药物制剂。